Literature DB >> 20122550

Colestimide, an anion exchange resin agent, can decrease the number of LDL particles without affecting their size in patients with hyperlipidemia.

Noriaki Kishimoto1, Satoshi Fujii, Hitoshi Chiba, Ichiro Sakuma, Hiroyuki Tsutsui.   

Abstract

OBJECTIVES: Recent studies have demonstrated that not only plasma low-density lipoprotein (LDL) levels, but also the number of small dense LDL particles are involved in the development of arteriosclerosis. Anion exchange resins can reduce plasma LDL levels and affect LDL particle size via increasing triglycerides. In the present study, the effects of short-term colestimide administration on LDL particle size were investigated.
METHODS: Obese patients with primary hyperlipidemia (n=21) were administered 3000 mg/day of colestimide for 1 month and fasting blood was obtained before and after the treatment. LDL particle size and number were measured by nuclear magnetic resonance (NMR) lipoprofile using magnetic resonance spectroscopy.
RESULTS: Levels of plasma LDL cholesterol decreased from 155.5 mg/dl to 128.1 mg/dl (p<0.001) and levels of apolipoprotein B decreased from 139.2 mg/dl to 120.6 mg/dl (p<0.001) by colestimide administration. Levels of high-density lipoprotein (HDL) cholesterol and triglyceride were unaltered. LDL particle size did not change, whereas LDL particle numbers decreased from 1920.3 nmol/l to 1568.8 nmol/l (p<0.01).
CONCLUSIONS: Short-term administration of colestimide to patients with hyperlipidemia reduced LDL particle numbers. LDL particle size was not changed. 2009 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20122550     DOI: 10.1016/j.jjcc.2009.08.006

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  4 in total

Review 1.  Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.

Authors:  Geoffrey Porez; Janne Prawitt; Barbara Gross; Bart Staels
Journal:  J Lipid Res       Date:  2012-05-01       Impact factor: 5.922

Review 2.  Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values.

Authors:  Robert S Rosenson; James A Underberg
Journal:  Cardiovasc Drugs Ther       Date:  2013-10       Impact factor: 3.727

3.  Effect of colestimide on the concentrations of polychlorinated dibenzo-p-dioxins, polychlorinated dizenzofurans, and polychlorinated biphenyls in blood of Yusho patients.

Authors:  Takashi Todaka; Akinori Honda; Masami Imaji; Yoshiko Takao; Chikage Mitoma; Masutaka Furue
Journal:  Environ Health       Date:  2016-06-04       Impact factor: 5.984

Review 4.  Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents.

Authors:  Sho Hasegawa; Masato Yoneda; Yusuke Kurita; Asako Nogami; Yasushi Honda; Kunihiro Hosono; Atsushi Nakajima
Journal:  Drugs       Date:  2021-06-17       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.